Xiaopeng Guo1, Hanhui Fu2, Haiyu Pang3, Bing Xing4. 1. Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People's Republic of China; China Pituitary Disease Registry Center, No. 1 Shuaifuyuan, Beijing 100730, People's Republic of China. 2. Peking Union Medical College, No. 5 Dongdansantiao, Beijing 100730, People's Republic of China. 3. Central Research Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People's Republic of China; Clinical Epidemiology Unit, International Epidemiology Network, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People's Republic of China. 4. Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People's Republic of China; China Pituitary Disease Registry Center, No. 1 Shuaifuyuan, Beijing 100730, People's Republic of China. Electronic address: xingbingemail@aliyun.com.
Abstract
OBJECTIVE: To perform a meta-analysis to evaluate the exact incidence of left ventricular hypertrophy, diastolic dysfunction and systolic dysfunction in patients with treatment-naïve acromegaly. METHODS: PubMed, EMBASE, Ovid MEDLINE, the Cochrane Library, Scopus, Science Citation Index Expand and PubMed Central were searched for eligible studies. Eligible data were extracted and evaluated using a fixed- or random-effects model. The Q test, I2 statistics for testing heterogeneity, the Newcastle-Ottawa Scale (NOS) for the retrospective appraisal of study quality, and Begg's test and Harbord's modified test for the evaluation of publication bias were used. RESULTS: Seven eligible studies were selected, and a total of 458 patients and 650 controls were included. Left ventricular hypertrophy was significantly more frequent in treatment-naïve acromegaly patients than in controls [odds ratio (OR) = 28.2, 95% confidence interval (CI) = 19.17-41.49] with a prevalence of 65.1%. Diastolic dysfunction was also common (50.5%) in acromegaly patients (OR = 15.62, 95% CI = 1.98-123.34). Moreover, 19.6% of patients presented abnormal systolic function with an OR of 13.1 (95% CI = 6.64-25.84). CONCLUSIONS: Patients with treatment-naïve acromegaly are at an increased risk of developing left ventricular hypertrophy, diastolic dysfunction and systolic dysfunction than the general population.
OBJECTIVE: To perform a meta-analysis to evaluate the exact incidence of left ventricular hypertrophy, diastolic dysfunction and systolic dysfunction in patients with treatment-naïve acromegaly. METHODS: PubMed, EMBASE, Ovid MEDLINE, the Cochrane Library, Scopus, Science Citation Index Expand and PubMed Central were searched for eligible studies. Eligible data were extracted and evaluated using a fixed- or random-effects model. The Q test, I2 statistics for testing heterogeneity, the Newcastle-Ottawa Scale (NOS) for the retrospective appraisal of study quality, and Begg's test and Harbord's modified test for the evaluation of publication bias were used. RESULTS: Seven eligible studies were selected, and a total of 458 patients and 650 controls were included. Left ventricular hypertrophy was significantly more frequent in treatment-naïve acromegalypatients than in controls [odds ratio (OR) = 28.2, 95% confidence interval (CI) = 19.17-41.49] with a prevalence of 65.1%. Diastolic dysfunction was also common (50.5%) in acromegalypatients (OR = 15.62, 95% CI = 1.98-123.34). Moreover, 19.6% of patients presented abnormal systolic function with an OR of 13.1 (95% CI = 6.64-25.84). CONCLUSIONS:Patients with treatment-naïve acromegaly are at an increased risk of developing left ventricular hypertrophy, diastolic dysfunction and systolic dysfunction than the general population.
Authors: Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier Journal: Rev Endocr Metab Disord Date: 2020-12 Impact factor: 6.514